Article
Receptor activator of nuclear factor kappa-B ligand (RANKL) but not sclerostin or gene polymorphisms is related to joint destruction in early rheumatoid arthritis.
Clinical rheumatology - 1 May 2017
Boman Antonia, Kokkonen Heidi, Ärlestig Lisbeth, Berglin Ewa, Rantapää-Dahlqvist Solbritt
Abstract excerpt
The aim of this study was to analyze relationships between receptor activator of nuclear factor kappa-B (RANKL), sclerostin and their gene polymorphisms with radiological progression in patients with early rheumatoid arthritis (RA). Patients with early RA (n = 407, symptomatic <1 year) (ARA criteria) examined radiologically at inclusion and after 24 months were consecutively included. Disease activity score and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
